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S U M M A R Y
Objectives: Human immunodeﬁciency virus (HIV) infection in Sub-Saharan Africa is complicated by
co-infection with hepatitis B and C viruses (HBV and HCV), which share similar transmission routes. The
aims of this study were to determine the prevalence of hepatitis B surface antigen (HBsAg)-positive and
HBsAg-negative HBV infection and of HCV infection among HIV-infected patients.
Methods: A cross-sectional study was conducted among treatment-naı¨ve HIV-positive adults in
Khartoum State. HBV, HCV, and HIV infections were detected using immunoassays for HBsAg, hepatitis B
core antibodies (anti-HBc), hepatitis C antibodies (anti-HCV), and HIV antibodies (anti-HIV), while real-
time PCR was used to measure HBV DNA.
Results: The mean age of the 358 patients was 35.2  9.3 years and the male to female ratio was 1.3:1.0.
The mean alanine aminotransferase (ALT) level was 10.9  18.0 U/l. Evidence of 23, current or past HBV
infection was detected in 62.8% of the patients. HBV DNA was detected in 96 patients (26.8%),
42 HBsAg-positive (11.7%) and 54 (15.1%) HBsAg-negative, indicating occult hepatitis B infection. Anti-
HCV was detected in 1.7%.
Conclusions: Evidence of HBV infection was detected in 26.8% of HIV patients with HBsAg-negative
infection, with viraemia detected in 15.1% of the patients. All HIV-infected patients should be screened
carefully for HBV infection with HBsAg and anti-HBc IgG antibodies prior to starting antiretroviral
therapy.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Human immunodeﬁciency virus (HIV) infection is a serious
health problem in Sub-Saharan Africa.1 HIV infection is compli-
cated by co-infection with other pathogens including hepatitis B
and C viruses (HBV and HCV), which share similar routes of
infection. Worldwide, it is estimated that over 240 million people
have a chronic HBV infection2 and 150 million have a chronic HCV* Corresponding author. Tel.: +27(0) 11 488 3100; fax: +27(0) 86 529 6806.
E-mail address: Anna.Kramvis@wits.ac.za (A. Kramvis).
http://dx.doi.org/10.1016/j.ijid.2014.07.004
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).infection.3 Globally there are 34 million people infected with HIV;
69% of them reside in Sub-Saharan Africa.1 Although the
introduction of antiretroviral therapy (ART) has decreased the
death rate and the incidence of AIDS-deﬁning diseases among
HIV-infected individuals, liver disease, mainly as a result of HBV or
HCV co-infection, has emerged as one of the leading causes of non-
AIDS-related mortality and morbidity.4 Co-infection with HBV or
HCV and HIV is characterized by more rapid progression of liver
disease, including accelerated ﬁbrosis, cirrhosis, and hepatocellu-
lar carcinoma.5,6
Sudan, located in north to east-central Africa, is endemic for
HBV infection, with HBV exposure rates ranging from 47%7 to 78%,8ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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hepatitis C antibody (anti-HCV) prevalence of 2.2%10 to 4.8%,11 and
a prevalence of HIV among the adult population of 0.9–1.4%.12
However, there is no clear knowledge about HBV in the setting of
HIV infection, and it is important to determine this and select
appropriate ART, especially as HIV patients may also develop
hepatic toxicity and lactic acidosis under ART, which is based on a
combination of drugs including lamivudine, stavudine, efavirenz,
and nevirapine.13
No studies have been carried out to determine the presence of
HBV DNA in the absence of HBsAg in HIV-positive Sudanese
patients. Thus the aims of this study were to determine the
prevalence of HBV and HCV infection and the prevalence of occult
hepatitis B infection (OBI) among adult Sudanese HIV patients.
2. Materials and methods
2.1. Patients
A cross-sectional study was conducted during the period
December 2010 to June 2012 in Khartoum, Sudan. All treatment-
naı¨ve adults (18 years and over) who tested positive for HIV
antibodies using an indirect ELISA, attending Omdurman Medical
AIDS Care Unit (OMACU) and Bashair Hospital HIV Treatment
Centre in Khartoum State, were included in the study. Children
younger than 18 years of age and pregnant women were excluded.
The study was approved by the Ethics Committee of the Faculty of
Medicine, University of Khartoum, the National Ethics Committee,
Federal Ministry of Health, Sudan, and by the Human Ethics
Committee of the University of the Witwatersrand, South Africa.
Written informed consent was obtained from all participants
before their enrolment.
2.2. Data collection
Data were collected using a specially designed questionnaire and
included basic demographic information including age and gender,
and potential risk factors for the transmission of infection, such as
multiple sexual partners, intravenous drug use, previous history of
jaundice and blood transfusion, and history of hepatitis B vaccina-
tion. All patients were classiﬁed according to the World Health
Organization (WHO) clinical staging of HIV-related disease.14
2.3. Collection and storage of samples
Ten millilitres (10 ml) of venous blood was collected from each
patient and divided into two blood collection tubes: 7 ml in
ethylenediaminetetraacetic acid (EDTA) tubes and 3 ml in plain
tubes for serum separation. Separated plasma and serum samples
were stored at 30 8C until further analysis.
2.4. Immunoassays
The detection of anti-HIV was done using an indirect ELISA kit
(Biorex; Antrium, UK). HBsAg, hepatitis B core antibody (anti-HBc)
IgM and IgG, hepatitis B e antigen (HBeAg) and antibodies (anti-
HBe), and anti-HCV were detected using immunoassays from
Diasource (Nivelles, Belgium). The immunoassay for hepatitis D
virus antibodies (anti-HDV) was from Diagnostic Automation, Inc.
(Calabasas, CA, USA). The manufacturer’s instructions were strictly
followed for all tests.
2.5. DNA extraction and quantitative real-time PCR
HBV DNA was extracted with the Sacace Ribo Virus Kit (HBV Real-
TM Quant; Sacace Biotechnologies, Como, Italy), as recommendedby the manufacturer. An internal control (HBV IC) with known viral
concentration (speciﬁc for each lot) was used to monitor the
ampliﬁcation and exclude any loss of genomic DNA or PCR inhibition
and to enable the precise calculation of the HBV viral load in the
samples. The extracted DNA was used immediately for PCR. Real-
time PCR was done using the HBV Real-TM Quant Kit (Sacace
Biotechnologies, Como, Italy). The extracted HBV DNA (12.5 ml) was
added to an equal volume of the reaction mixture provided in the kit.
With each run, three known standards of the HBV DNA (QS1 HBV,
QS2 HBV, and QS3 HBV) and the three internal control standards
(QS1 IC, QS2 IC, and QS3 IC) were used to calculate the viral copy
numbers. Real-time PCR was done in accordance with the
manufacturer’s instructions, as follows: stage 1, 95 8C for 15 min;
stage 2, a two-temperature cycle of 95 8C for 20 s and 60 8C for 40 s,
which was repeated 42 times. Cy3 dye was used for the sample and
FAM for the internal control. The signals from these dyes were
calculated and presented as numbers. The sensitivity of the assay is
approximately 20 genome copies/ml, which is equivalent to 12 IU/
ml (1.1 log10 IU/ml), conversion factor = 1.7.
2.6. Statistical analysis
The statistical analysis was done using SPSS software program
version 20 (SPSS Inc., Chicago, IL, USA); the Chi-square test using
the t-statistic was performed, and signiﬁcance was set at p < 0.05.
3. Results
A total of 358 HIV-infected patients were enrolled in the study.
Their mean ( standard deviation) age was 35.2  9.3 years; the male
to female ratio was 1.3:1.0. The mean alanine aminotransferase (ALT)
level of the study population was 10.9  18.0 U/l. Demographic data
of the study population as a whole and stratiﬁed according to anti-
HBc IgG, as well as risk factors for acquiring HBV infection are shown
in Table 1.
3.1. HBV serology
Of the 358 patients, 225 (62.8%) were anti-HBc IgG-positive,
indicating previous exposure to HBV infection. The mean age and
ALT level of this subpopulation were 35.3  9.4 years and
11.0  20.9 U/l, respectively, and these values did not differ from
those of the population as a whole. Only four patients (1.1%) reported
being vaccinated against HBV infection, however anti-hepatitis B
surface antibodies (anti-HBs) were not tested. Male gender and
intravenous drug use were found to be risk factors for positivity for
HBV markers (p < 0.05) (Table 1).
3.2. HBsAg-positive patients
Forty-two patients (11.7%) were HBsAg-positive. The mean age
and ALT level of this group were 34.7  8.7 years and 9.8  7.2 U/l,
respectively, and these values did not differ from those of the
population of 225 patients who were anti-HBc IgG-positive. Eight
patients (19.0%) were HBeAg-positive and anti-HBe-negative,
24 patients (57.1%) were HBeAg-negative and anti-HBe-positive,
and 10 patients (23.8%) were negative for both HBeAg and anti-HBe.
All patients were negative for anti-HDV.
3.3. Viral loads
HBV DNA was detected by PCR in 96 patients (26.8%); all were
anti-HBc IgG-positive. Demographic data for patients with
detectable HBV DNA on PCR and risk factors for acquisition are
shown in Table 2. Risk factors associated with HBV DNA positivity
included blood transfusion, previous dental procedures, history of
Table 1
Demographic data and risk factors for HBV exposure of 358 HIV-positive Sudanese adults
Variable Number of patients tested
(N = 358)
Number positive for anti-HBc IgG
(n = 225)
Number negative for anti-HBc IgG
(n = 133)
p-Value
Gender Male 203 (56.7%) 139 (61.8%) 64 (48.1%) 0.012a
Female 155 (43.3%) 86 (38.2%) 69 (51.9%)
Marital status Married 214 (59.8%) 136 (60.4%) 78 (58.6%) 0.896
Single 82 (22.9%) 50 (22.2%) 32 (24.1%)
Divorced/widowed 62 (17.3%) 39 (18.8%) 23 (17.3%)
Multiple sexual partners Yes 144 (40.2%) 95 (42.2%) 49 (36.8%) 0.316
No 214 (59.8%) 130 (57.8%) 84 (63.2%)
Surgery Yes 65 (18.2%) 37 (16.4%) 28 (21%) 0.274
No 293 (81.8%) 188 (83.6%) 105 (79%)
Blood transfusion Yes 38 (10.6%) 20 (8.9%) 18 (13.5%) 0.168
No 320 (89.4%) 205 (91.1%) 115 (86.5%)
Dental procedures Yes 92 (25.7%) 54 (24.0%) 38 (28.6%) 0.339
No 266 (74.3%) 171 (76.0%) 95 (71.4%)
Intravenous drug use Yes 5 (1.4%) 1 (0.4%) 4 (3%) 0.046a
No 353 (98.6%) 224 (99.6%) 129 (97%)
History of jaundice Yes 111 (31.0%) 78 (34.7%) 33 (24.8%) 0.51
No 247 (69.0%) 147 (65.3%) 100 (75.2%)
HBV vaccination Yes 4 (1.1%) 2 (0.9%) 2 (1.5%) 0.593
No 354 (98.9%) 223 (99.1%) 131 (98.5%)
WHO classiﬁcation Stage 1 and 2 126 (35.2%) 66 (29.3%) 60 (45.1%) 0.168
Stage 3 and 4 232 (64.8%) 159 (70.7%) 73 (54.9%)
HBV, hepatitis B virus; anti-HBc, hepatitis B core antibodies; WHO, World Health Organization.
a Signiﬁcant risk factor.
Table 2
Comparison between patients who were HBV DNA-positive and patients who were HBV DNA-negative on PCR, among 358 HIV-infected patients
Variable Number of patients tested
(N = 358)
HBV DNA-positive
(n = 96)
HBV DNA-negative
(n = 262)
p-Value
Gender Male 203 (56.7%) 59 (61.5%) 144 (55%) 0.272
Female 155 (43.3%) 37 (38.5%) 118 (45%)
Marital status Married 214 (59.8%) 62 (64.6%) 152 (58%) 0.342
Single 82 (22.9%) 24 (25%) 58 (22.1%)
Divorced/widowed 62 (17.3%) 10 (10.4%) 52 (19.8%)
Multiple sexual partners Yes 144 (40.2%) 42 (43.8%) 102 (38.9%) 0.410
No 214 (59.8%) 54 (56.2%) 160 (61.1%)
History of surgery Yes 65 (18.2%) 17 (17.7%) 48 (18.3%) 0.894
No 293 (81.8%) 79 (82.3%) 214 (81.7%)
Blood transfusion Yes 38 (10.6%) 5 (5.2%) 33 (12.6%) 0.044a
No 320 (89.4%) 91 (94.8%) 229 (87.4)
Dental procedures Yes 92 (25.7%) 16 (16.7%) 76 (29%) 0.018a
No 266 (74.3%) 80 (83.3%) 186 (71%)
Intravenous drug use Yes 5 (1.4%) 0 5 (1.9%) 0.173
No 353 (98.6%) 96 (100%) 257 (98.1%)
History of jaundice Yes 111 (31.0%) 38 (39.6%) 73 (27.9%) 0.034a
No 247 (69.0%) 58 (60.4%) 189 (72.1%)
HBV vaccination Yes 4 (1.1%) 1 (1%) 3 (1.1%) 0.934
No 354 (98.9%) 95 (99%) 259 (98.9%)
WHO classiﬁcation Stage 1 and 2 126 (35.2%) 23 (24%) 103 (39.3%) 0.037a
Stage 3 and 4 232 (64.8%) 73 (76%) 159 (60.7%)
HBV, hepatitis B virus; WHO, World Health Organization.
a Signiﬁcant risk factor.
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Forty-two patients (11.7%) were HBsAg-positive and 54 patients
(15.1%) were HBsAg-negative, indicating occult infection (Table 3).
The only risk factor that differentiated HBsAg-positive and HBsAg-
negative infections was a history of jaundice (Table 3). Moreover,
the overall median (interquartile range) viral load was 2.9 (1.7–
4.1) log10 IU/ml, with HBsAg-positive individuals having signiﬁ-
cantly higher viral loads of 3.2 (3.3–6.6) log10 IU/ml compared to
HBsAg-negative patients with viral loads of 1.7 (1.3–2.7) log10
IU/ml. Eight HBsAg-positive, HBeAg-positive, anti-HBe-negative
patients had viral loads of 5.6 log10 IU/ml, 24 HBsAg-positive,
HBeAg-negative, anti-HBe-positive patients had viral loads of
3.8 log10 IU/ml, and 10 HBsAg-positive, HBeAg/anti-HBe-negative
had viral loads of 3.9 log10 IU/ml. Thirty-ﬁve (9.8%) HBsAg-negative
patients had a viral load < 2.3 log10 IU/ml (< 200 IU/ml) and 19(5.3%) had viral loads >2.3 log10 IU/ml (>200 IU/ml). One patient
was reactive in both anti-HBc IgG and anti-HBc IgM; the patient
was HBsAg-negative with normal ALT and had detectable HBV
DNA on PCR indicating a recent HBV infection or an HBV
reactivation in a patient with OBI.
3.4. HCV infection
Six patients (1.7%), ﬁve of whom were female, tested positive
for anti-HCV antibodies; their mean age was 34.3  12.9 years and
mean ALT level was 6.0  3.8 U/l. None of them was an intravenous
drug user and there were no signiﬁcant risk factors for HCV infection.
Five of these patients were anti-HBc IgG-positive, with two having
detectable HBV DNA on PCR. One patient was HBsAg-positive, while the
second patient was HBsAg-negative, indicating occult HBV infection.
Table 3
Comparison between HBsAg-positive and HBsAg-negative patients among 96 HIV-infected patients with detectable HBV DNA on PCR
Variable Number of patients tested
(n = 96)
HBsAg-positive
(n = 42)
HBsAg-negative
(n = 54)
p-Value
Gender Male 59 (61.5%) 24 (57.1%) 35 (64.8%) 0.444
Female 37 (38.5%) 18 (42.9%) 19 (35.2%)
Marital status Married 62 (64.6%) 28 (66.7%) 34 (63%) 0.819
Single 24 (25%) 11 (26.2%) 13 (24%)
Divorced/widowed 10 (10.4%) 3 (7.2%) 7 (13%)
Multiple sexual partners Yes 42 (43.8%) 18 (42.9%) 24 (44.4%) 0.876
No 54 (56.2%) 24 (57.1%) 30 (55.6%)
Surgery Yes 17 (17.7%) 8 (19%) 9 (16.7%) 0.762
No 79 (82.3%) 34 (81%) 45 (83.3%)
Blood transfusion Yes 5 (5.2%) 3 (7.1%) 2 (3.7%) 0.452
No 91 (94.8%) 39 (92.9%) 52 (96.3%)
Dental procedures Yes 16 (16.7%) 9 (21.4%) 7 (13%) 0.270
No 80 (83.3%) 33 (78.6%) 47 (87%)
Intravenous drug use Yes 0 0 0 -
No 96 (100%) 42 (100%) 54 (100%)
History of jaundice Yes 38 (39.6%) 23 (54.8%) 15 (27.8%) 0.007a
No 58 (60.4%) 19 (45.2%) 39 (72.2%)
HBV vaccination Yes 1 (1%) 1 (2.4%) 0 0.254
No 95 (99%) 41 (97.6%) 54 (100%)
WHO classiﬁcation Stage 1 and 2 23 (24%) 11 (26.2%) 12 (22.2%) 0.947
Stage 3 and 4 73 (76%) 31 (73.8%) 42 (77.8%)
HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; WHO, World Health Organization.
a Signiﬁcant risk factor.
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The 62.8% exposure rate to HBV infection and prevalence of
HBsAg of 11.7% detected in the HIV-positive Sudanese patients in
the present study did not differ from HBV exposure rates found
previously in HIV-negative patients, with rates ranging from 47%7
to 78%8 and the prevalence of HBsAg from 6.9%7 to 18.7%.9
Although HBc IgG-positive, HBsAg-positive serology can also be
observed during late acute HBV infection, in Sub-Saharan Africa
this would be unlikely given the epidemiology of HBV infection in
the region, thus we believe that the 11.7% of patients with positive
HBsAg had chronic HBV infection.
The prevalence of HCV antibodies of 1.7% was also similar to
HCV prevalence rates in HIV-negative patients of 2.2%10 to 4.8%11
in previous studies. Similar exposure rates to HBV and HCV among
HIV-positive and HIV-negative individuals in Sub-Saharan African
countries have been reported.15 In Ethiopia, in HIV-positive
patients, the exposure to HBV was reported to be 47.5% and
prevalence of HBsAg 3.9%, compared to 41.9% exposure to HBV and
5.4% HBsAg positivity in HIV-negative patients.16 In Uganda,
exposure to HBV and prevalence of HBsAg were reported to be 59%
and 8.3%, respectively, in HIV-positive patients, compared to 51.9%
and 10.4%, respectively, in HIV-negative patients.17 A study in
Mozambique in HIV-positive patients revealed exposure to HBV to
be 69.6%, HBsAg 10.6%, and HCV antibodies 1.4%, compared to
62.5%, 9.0%, and 1.5%, respectively, in HIV-negative individuals.18
The similar frequencies of HBV infection in HIV-infected and
HIV-uninfected individuals in regions of high HBV endemicity such
as in Sub-Saharan Africa, suggest that the mode and timing of
transmission of HBV are generally independent to those of HIV. In
Sub-Saharan Africa, most HBV infections occur in childhood either
perinatally or more often through horizontal transmission such as
close contact within households, medical procedures using non-
sterile equipment, and through traditional medical practices long
before exposure to HIV.19,20 This is in contrast to countries with
low HBV endemicity such as the USA, Europe, and Australia, where
HBV is frequently transmitted sexually or via intravenous drug
use,21 and may often be co-transmitted with HIV. Here, although
the HBV prevalence in HIV-positive patients may be similar to that
found in high endemicity regions (with Soriano et al.,22 for
example, reporting a 7.1% HBsAg positivity), it is relatively higherwhen compared to HIV-negative patients. Studies have also shown
that following acute HBV infection, HIV patients are more likely to
develop chronic infection than non-HIV patients and this may
explain why HIV patients have a higher rate of chronic HBV
infection in low endemicity regions.21,23
The present study showed a slightly higher prevalence of HBeAg
(19%) among HBV/HIV co-infected patients when compared with
our previous report on the prevalence of HBeAg among HIV-
negative patients, in which only 12% were HBeAg-positive.24 This,
however, was not signiﬁcantly different. A similar trend was
reported from Zambia, where HBeAg was positive in 25% of HIV-
positive patients compared to 8.5% among HIV-negative patients.25
It is possible that HIV, by causing immunosuppression, may delay
or prevent seroconversion to the inactive carrier phase in patients
with chronic HBV infection.21 It has been demonstrated that
efﬁcient restoration of immunity after the introduction of ART
leads to high rates of seroconversion, especially in patients in the
immunoactive phase of HBV infection.26 However, there is also the
possibility that the HIV co-infected patients, who were signiﬁ-
cantly younger than the mono-infected liver disease patients, did
not have enough time to seroconvert or were recently infected
with HBV. Patients infected with HBV/HIV had higher HBV viral
loads compared to HBV mono-infected patients (p < 0.05)24 and
also lower ALT levels, within the normal range, compared to the
patients infected with HBV only (p < 0.05).24 The relatively low
ALT levels have also been demonstrated in studies from South
Africa, where there was no signiﬁcant difference in ALT levels
among HIV patients serologically positive or negative for HBV
infection.27 The immunosuppression caused by the HIV infection is
responsible for these differences28 and can account for the low rate
of clinical manifestations of liver disease in the study population.
In addition to this risk, ART may cause further liver damage,
either through direct toxicity or through idiosyncratic reactions.29
HBV/HIV co-infection is known to increase the risk of hepatotox-
icity from ART when compared to other HIV patients without HBV
or HCV co-infection.13,30 In Sub-Saharan Africa, however, this risk
is not entirely attributable to ART but may also be a result of
elevated levels of HBV DNA in the serum.31
HIV infection is also a known risk factor for the development of
OBI;32 this is characterized by two main criteria: the absence of
HBsAg and low viral replication. This has been reported in several
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HBsAg too low to be detected using current serological tests and
the presence of anti-HBc IgG as the only serological evidence of
exposure to the virus, referred to as ‘isolated anti-HBc’.33 In this
study, 96 patients (26.8%) had detectable HBV DNA on PCR, all of
them were HBc IgG-positive, 11.7% were HBsAg-positive, and
54 patients (15.1%) were HBsAg-negative indicating ‘occult’
infection. OBI was further deﬁned by the Taormina Consensus
Conference in 2008 as the ‘‘presence of HBV DNA in the liver (with
detectable or undetectable HBV DNA in serum) of individuals
testing HBsAg-negative with currently available assays and a
serum HBV DNA of <2.3 log10 IU/ml (<200 IU/ml) when
detectable’’.34 In this study, 35 (9.8%) HBsAg-negative patients
had a viral load <2.3 log10 IU/ml (<200 IU/ml) and 19 (5.3%) had
viral loads >2.3 log10 IU/ml (>200 IU/ml). Some individuals with
chronic HBV infection may be HBsAg-negative but have HBV DNA
levels comparable to patients with positive HBsAg (>2.3 log10
IU/ml; >200 IU/ml). These individuals may be infected with HBV
variants with S gene escape mutants, which do not express HBsAg
on serology, as pre-S mutations may prevent HBsAg secretion.35 In
many HIV patients with OBI, the viral load may be higher than
suggested by the Taormina conference, which did not deal
explicitly with HIV co-infection. A similar study from South Africa
has reported positive HBV DNA in 23.8% of HIV patients; 8.7% were
HBsAg-positive and 15.7% were HBsAg-negative, with a viral load
of <2.3 log10 IU/ml (<200 IU/ml) detected in 6.7% of HBsAg-
negative patients.27 OBI has been demonstrated in 21.3% of
HIV-infected patients from the Cote d’Ivoire36 and in 10.5% of cases
from the USA.37
While HIV is treated with a combination of three drugs, which
include lamivudine, stavudine, efavirenz, and nevirapine,13 only
lamivudine is active against HBV. While earlier reports have
suggested rates of HBV resistance of up to 20% per year with
lamivudine monotherapy in HBV/HIV co-infected patients,38
reports from Sub-Saharan Africa have suggested that although
lamivudine resistance can occur in the setting of incomplete HBV
suppression, this is infrequently observed among HBV/HIV co-
infected patients who are HBeAg-negative with low baseline HBV
levels.39 In 2010, the WHO recommended the introduction of ART
that includes tenofovir in combination with lamivudine or
emtricitabine as ﬁrst-line therapy in all HBV/HIV co-infected
patients needing treatment in order to reduce the development of
HBV drug resistance.40
Interestingly, in this study, out of 96 patients with detectable
HBV DNA, HIV/HBV/HCV triple infection was detected in two
patients (2%); none had HIV/HBV/HDV triple infection. This is in
contrast to another study in which HIV/HBV/HCV was detected in
6% and HIV/HBV/HDV was detected in 4% of patients.41 It is
generally thought that HBV replication is signiﬁcantly reduced in
HCV and HDV triple infections. The low HCV triple infection in this
study could be explained by the low prevalence of HCV of only
2.2–4.8% found in Sudan.10,11 However, the absence of HDV triple
infection is difﬁcult to explain considering that HDV antibodies
were detected in 9.0% of patients with chronic HBV mono-
infection.42
Limitations of the present study include not testing for anti-HBs
to determine immunity to HBV in HBsAg-negative patients, not
determining CD4 counts or HIV viral loads, and not performing
nucleic acid testing for HCV, liver ﬁbrosis assessment, or
multivariable analysis.
In conclusion, in Sudan exposure rates to HBV infection and the
prevalence of HBsAg and HCV antibodies among adult HIV-
infected patients were found to be similar to those reported for
HIV-negative patients in previous studies. HBsAg-negative HBV
infection was detected in 15.1% of patients. The prevention of
HBV and HIV through education and vaccination against HBV isessential in our setting. All HIV-infected patients should be
screened carefully for HBV infection with HBsAg and anti-HBc IgG
antibodies prior to starting ART, which should include tenofovir
and lamivudine (or emtricitabine) as ﬁrst-line therapy. Although
PCR testing would detect OBI, which would be missed by
serological testing alone, it is too expensive to include as a routine
screening test in Sudan. Considering that nucleic acid testing can
detect both overt and occult HBV infection, cost-effective
alternatives could include PCR testing only in patients with
clinical or laboratory evidence of active liver disease, or the
development of a cheap, rapid test for HBV DNA detection.
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